Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.

Mansfield, A S; Wei, Z; Mehra, R; Shaw, A T; Lieu, C H; Forde, P M; Drilon, A E; Mitchell, E P; Wright, J J; Takebe, N; Sharon, E; Hovelson, D; Tomlins, S; Zeng, J; Poorman, K; Malik, N; Gray, R J; Li, S; McShane, L M; Rubinstein, L V; Patton, D; Williams, P M; Hamilton, S R; Conley, B A; Arteaga, C L; Harris, L N; O'Dwyer, P J; Chen, A P; Flaherty, K T

Mansfield, A S; Wei, Z; Mehra, R; Shaw, A T; Lieu, C H; Forde, P M; Drilon, A E; Mitchell, E P; Wright, J J; Takebe, N; Sharon, E; Hovelson, D; Tomlins, S; Zeng, J; Poorman, K; Malik, N; Gray, R J; Li, S; McShane, L M; Rubinstein, L V; Patton, D; Williams, P M; Hamilton, S R; Conley, B A; Arteaga, C L; Harris, L N; O'Dwyer, P J; Chen, A P; Flaherty, K T.

Afiliação

Mansfield AS; Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. Mansfield.aaron@mayo.edu.
Wei Z; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA.
Mehra R; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA.
Shaw AT; Massachusetts General Hospital, Boston, MA, USA.
Lieu CH; University of Colorado Cancer Center, Aurora, CO, USA.
Forde PM; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Drilon AE; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
Mitchell EP; Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Wright JJ; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Takebe N; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Hovelson D; Strata Oncology, Inc, Ann Arbor, MI, USA.
Tomlins S; Strata Oncology, Inc, Ann Arbor, MI, USA.
Zeng J; Caris Life Sciences, Irving, TX, USA.
Poorman K; Caris Life Sciences, Irving, TX, USA.
Malik N; Tempus, Chicago, IL, USA.
Gray RJ; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA.
Li S; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA.
McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Patton D; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD, USA.
Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Hamilton SR; City of Hope, Duarte, CA, USA.
Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Arteaga CL; Simmons Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA, USA.
Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Flaherty KT; Massachusetts General Hospital, Boston, MA, USA.

NPJ Precis Oncol ; 6(1): 13, 2022 Mar 01.

Article em En | MEDLINE | ID: mdl-35233056

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Risk_factors_studies Idioma: En Revista: NPJ Precis Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google